Assessment Of [I-125]Wye-230949 As A Novel Histamine H-3 Receptor Radiopharmaceutical

Histamine H-3 receptor therapeutics have been proposed for several diseases such as schizophrenia, attention deficit hyperactivity disorder, Alzheimer's disease and obesity. We set out to evaluate the novel compound, [I-125] WYE-230949, as a potential radionuclide imaging agent for the histamine H-3 receptor in brain. [I-125] WYE-230949 had a high in vitro affinity for the rat histamine H-3 receptor (K-d of 6.9 nM). The regional distribution of [I-125] WYE-230949 binding sites in rat brain, demonstrated by in vitro autoradiography, was consistent with the known distribution of the histamine H-3 receptor. Rat brain uptake of intravenously injected [I-125] WYE-230949 was low (0.11 % ID/g) and the ratio of specific: non-specific binding was less than 1.4, as determined by ex vivo autoradiography. In plasma, metabolism of [I-125] WYE-230949 into a less lipophilic species occurred, such that less than 38% of the parent compound remained 30 minutes after injection. Brain uptake and metabolism of [I-125] WYE-230949 were increased and specific binding was reduced in anaesthetised compared to conscious rats. [I-125]WYE230949 is not a potential radiotracer for imaging rat histamine H-3 receptors in vivo due to low brain uptake, in vivo metabolism of the parent compound and low specific binding.